Sun Pharma Advanced Research Co (NSE:SPARC) Change In Working Capital : ₹0.0 Mil (TTM As of Mar. 2025)

View and export this data going back to 2007. Start your Free Trial

What is Sun Pharma Advanced Research Co Change In Working Capital?

Sun Pharma Advanced Research Co's change in working capital for the quarter that ended in Mar. 2025 was ₹0.0 Mil.

Sun Pharma Advanced Research Co's change in working capital for the fiscal year that ended in Mar. 2025 was ₹-468.6 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Sun Pharma Advanced Research Co Change In Working Capital Historical Data

The historical data trend for Sun Pharma Advanced Research Co's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sun Pharma Advanced Research Co Change In Working Capital Chart

Sun Pharma Advanced Research Co Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Change In Working Capital

Get a 7-Day Free Trial

-478.76

-260.53

1,411.08

-273.40

-468.60

Sun Pharma Advanced Research Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Working Capital	Get a 7-Day Free Trial															-	-	-	-	-

Sun Pharma Advanced Research Co Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.0 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Sun Pharma Advanced Research Co Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Sun Pharma Advanced Research Co's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Sun Pharma Advanced Research Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sun Pharma Advanced Research Co Ltd (NSE:SPARC) » Definitions » Change In Working Capital

Traded in Other Exchanges

532872:India

Address

Off Mahakali Caves Road, 17-B, Mahal Industrial Estate, Andheri (East), Mumbai, MH, IND, 400093

Website

https://www.sparc.life

Sun Pharma Advanced Research Co Ltd is an Indian specialty and generic drug manufacturing company. The company has identified pharmaceuticals research and development as its only reportable segment. The company is focused on drug discovery in focused therapy areas such as cancer and anti-inflammatory treatments. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. It derives maximum revenue from India and also has its presence in othe4r countries.

Sun Pharma Advanced Research Co Headlines

No Headlines